PMID- 1878842
OWN - NLM
STAT- MEDLINE
DCOM- 19910927
LR  - 20190619
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 68
IP  - 6 Suppl
DP  - 1991 Sep 15
TI  - Use of intravenous immunoglobulin in chronic lymphocytic leukemia. A brief 
      review.
PG  - 1437-9
AB  - Chronic lymphocytic leukemia (CLL) is a disorder with multiple defects leading to 
      an increased susceptibility to infection. Hypogammaglobulinemia is present in 
      about 20% to 70% of patients with CLL. Intravenous immunoglobulin (IVIG) 
      supplementation (400 mg/kg body weight every 3 weeks) prevented bacterial 
      infections in these patients. An ongoing study is being conducted to compare 
      doses of 250 mg/kg/mo with those of 500 mg/kg/mo in 36 patients included so far. 
      As of this writing, the rate of infection in the two treatment groups was not 
      significantly different, and no substantial loss of protection against bacterial 
      infection was found in the lower-dose group. It seems likely that the lower dose 
      is almost as effective as the standard therapy. If this is so, cost savings would 
      be substantial.
FAU - Dicato, M
AU  - Dicato M
AD  - Centre Hospitalier de Luxembourg, United Kingdom.
FAU - Chapel, H
AU  - Chapel H
FAU - Gamm, H
AU  - Gamm H
FAU - Lee, M
AU  - Lee M
FAU - Ries, F
AU  - Ries F
FAU - Marichal, S
AU  - Marichal S
FAU - Wirth, C
AU  - Wirth C
FAU - Griffith, H
AU  - Griffith H
FAU - Brennan, V
AU  - Brennan V
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
SB  - IM
MH  - Humans
MH  - *Immunization, Passive/adverse effects
MH  - Infusions, Intravenous
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*therapy
RF  - 11
EDAT- 1991/09/15 00:00
MHDA- 1991/09/15 00:01
CRDT- 1991/09/15 00:00
PHST- 1991/09/15 00:00 [pubmed]
PHST- 1991/09/15 00:01 [medline]
PHST- 1991/09/15 00:00 [entrez]
AID - 10.1002/1097-0142(19910915)68:6+<1437::aid-cncr2820681406>3.0.co;2-h [doi]
PST - ppublish
SO  - Cancer. 1991 Sep 15;68(6 Suppl):1437-9. doi: 
      10.1002/1097-0142(19910915)68:6+<1437::aid-cncr2820681406>3.0.co;2-h.